– USA, CA – Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today completed the succession plan previously announced with the promotion of Kelly Huang, Ph.D., to Chief Executive Officer.
Dr. Huang has served as Obalon’s Chief Operating Officer since September 2017, and was promoted to President in August 2018. Andy Rasdal, who has served as CEO since Obalon’s founding in 2008 will serve as Executive Chairman.
“More than a year ago, we brought Kelly in as Chief Operating Officer to lead commercial operations,” said Mr. Rasdal. “Kelly has continued to demonstrate that he is a strong and capable leader, and we believe he will be effective as CEO of Obalon. I intend to stay actively involved as Executive Chairman, primarily to serve as a resource to Kelly, and will also focus on several key strategic projects to help build the intragastric balloon market and create sustainable value for Obalon.”
About Dr Huang
Prior to joining Obalon, Dr. Huang was the General Manager for Galderma Laboratories, L.P., Aesthetic & Corrective, where he led business strategy, execution, and development. During his tenure, key aesthetic brands grew through product innovation, marketing strategies, and value-added services for physician customers that allowed for better patient acquisition, retention and more efficient clinical logistics. Prior to Galderma, Dr. Huang was a President on Endo Pharmaceutical’s Executive Committee, responsible for leadership of the urology device and services division, affording him extensive experience in medical devices. Dr. Huang was also at Johnson & Johnson for more than 16 years, across a variety of divisions, from research and development to professional sales and marketing. Dr. Huang earned his Doctorate and Masters degrees in Chemical Engineering from Stanford University in California.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence.
For more information : https://www.obalon.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.